Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578876 | 0.82 | POLB (0.46) | ESR2POLBESR1 | |
| SCHEMBL22929 | 0.82 | — | — | |
| SCHEMBL3231007 | 0.79 | ESR2 (0.44) | ESR2POLBESR1 | |
| SCHEMBL17316818 | 0.78 | — | — | |
| SCHEMBL27684182 | 0.78 | SLC18A3 (0.50) | ESR2 | |
| SCHEMBL3233086 | 0.78 | ESR2 (0.41) | ESR2POLBESR1 | |
| SCHEMBL17729484 | 0.76 | DGAT1 (0.32) | DGAT1IDH1 | |
| SCHEMBL14356440 | 0.75 | ESR2 (0.44) | ESR2DGAT1ESR1 | |
| SCHEMBL1516060 | 0.75 | ESR2 (0.63) | ESR2ESR1 | |
| SCHEMBL26086875 | 0.75 | TSHR (0.42) | ESR2DGAT1ESR1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | claimed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | claimed |
| EP-3215500-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | claimed |
| WO-2016073420-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | claimed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | disclosed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | disclosed |
| EP-3215500-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| WO-2016073420-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| CN-104447792-A | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI AVENTIS | 2015-03-25 | — | — | CN | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| EP-2475428-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
| CN-101675060-A | Substituted dihydro and tetrahydro oxazolopyrimidinones, their preparation and use | SANOFI AVENTIS | 2010-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ESR2 3603/4885DGAT1 1780/4885POLB 1125/4885 |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | ESR2 1257/4885DGAT1 81/4885POLB 4264/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ESR2 3603/4885DGAT1 1780/4885POLB 1125/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ESR2 3603/4885DGAT1 1780/4885POLB 1125/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | ESR2 1257/4885DGAT1 81/4885POLB 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.